NEW YORK, Jan. 26, 2016 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against HeartWare International, Inc. (“Heartware” or the “Company”) (Nasdaq:HTWR) in the United States District Court for the Southern District of New York on behalf of a class consisting of all persons or entities who purchased HeartWare securities between June 10, 2014 and January 11, 2016, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that the Company and certain of its senior executives violated provisions of the Exchange Act by making numerous false and misleading statements and omissions of material fact, including in press releases and in statements during conferences and conference calls with analysts and investors. Specifically, the Complaint alleges that after the U.S. Food and Drug Administration (“FDA”) issued a Warning Letter identifying numerous manufacturing and other regulatory failures at the Company’s sole manufacturing facility, Defendants falsely assured investors that the Company had addressed those problems, and that they therefore posed no risk to the clinical trials or timely approval of MVAD, a pump that HeartWare is presently developing.
Following a series of disclosures regarding adverse effects in certain clinical trial patients, shares of HeartWare have declined from a close of $87.73 per share on June 25, 2014, to a close of just $34.50 per share on January 22, 2016.
If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.


Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 



